Telum Therapeutics secured €18 million in Series A funding, its first major financing round, to advance its lead program targeting hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) through Phase 1 clinical development. The round was led by AMR Action Fund, with participation from Inveready and existing investors. These funds will also support the advancement of Telum's broader pipeline for Gram-negative and Gram-positive pathogens.